News & Insights
Besides sharing our hands-on expertise in projects, we regularly share industry insights, updates, and news.
Press Release: NecstGen Recurring Customer Pan Cancer T Secures € 4.25 Million Seed Extension
NecstGen Recurring Customer Pan Cancer T secures 4.25 million Euro seed extension and continues its path to the clinic to treat solid tumors.
Collaboration UMC Utrecht for Bone Regeneration Therapy
NecstGen and UMC Utrecht partner to advance bone regeneration therapy using MSC-derived spheroids, marking a significant step in regenerative medicine.
Webinar LV Process for CAR T
Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process.
Webinar CAR Therapy Today & Tomorrow
Explore available CAR therapies, differentiation, development challenges, and lessons learned from our expert scientist.
iPSC Reprogramming & Transdifferentiation
iPSC reprogramming and cell transdifferentiation offer exciting cellular science opportunities. Learn how these approaches are changing regenerative medicine and cellular therapy.
Differentiation of Human iPSCs
Human induced pluripotent stem cells (iPSCs) offer great potential for the future of medicine. We look into the world of human iPSCs, exploring their incredible promise and the critical significance of directing their development towards specialised cell lineages.
iPSC Development: Technical, Clinical, and Regulatory Hurdles
Induced pluripotent stem cells hold immense promise in revolutionising medicine through patient-specific therapies. However, their clinical development presents intricate challenges, including safety validation, differentiation complexities, and ethical considerations.
EIC Awards €2.5 Million Grant
Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Council (EIC) for a significant grant of €2.5 million.
Exploring the Impact of iPSC-Derived Organoids on Biomedical Science
Discover the role of iPSC-derived organoids in biomedical science, advancing our understanding of human biology and opening doors.
The Ethical Advantages of iPSCs
Stem cell research has long been mired in ethical controversies, primarily around embryonic stem cell use, which involves complex moral and philosophical debates. The advent of iPSCs presents a turning point, promising a less contentious path forward in regenerative medicine.
Webinar
Transforming Your LV Process for CAR T to a Scalable, GMP-Ready ProcessKey areas of focus include: Transitioning from research to clinical application presents numerous challenges, particularly for CAR T developers, academic institutions, and small companies at a...
Webinar Product Quality For Cell Therapies
This session is all about building and testing strategies to set the groundwork for effective development and testing in your own work.
NecstGen and Aarhus University Collaborate in Groundbreaking Initiative for GMP-Compliant Stem Cell Production
NecstGen, Netherlands, a pioneering biotechnology center and non-profit CDMO specialising in Gene and Cell therapy, is proud to announce its groundbreaking collaboration with the Center for Gene and Cellular Therapy at Aarhus University Hospital (AUH), Denmark.
IPSCs, what are they? And what is their potential?
What are iPSCs? And how can we harness induced Pluripotent Stem Cells’ potential for the betterment of patient care?
Webinar iPSC Banking & Derivation
iPSC Banking & Derivation Ever wondered how to transition from bench to GMP suitable processes in the iPSC-derived therapies field? Yes? Watch the webinar replay on iPSC Derivation & Banking.Key areas of focus include: Transitioning from Bench to GMP Suitable...
NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology
NecstGen and ProteoNic announce the successful development of improved lentiviral vectors for Cell and Gene Therapy, leveraging ProteoNic’s premium 2G UNic™ technology.
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
bioMérieux partners with NecstGen
bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
NecstGen Announces Major Milestone – GMP Manufacturing License
The NecstGen team is happy to announce that is has received its GMP Manufacturing License.
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development.
Webinar: How to develop your Cell Therapy manufacturing process
How do you translate your Cell Therapy processes to GMP? What are the challenges of bringing an iPSC-based therapy to the patient? How to set up a CAR-T manufacturing process?
Press Release Horizon Europe Grant BioProS
As part of the Horizon Europe framework, NecstGen has joined an international consortium, that will work to develop Biointelligent Sensors for real time in production measurement and control of therapeutics including Cell and Gene Therapies.
Cell and Gene Therapy companies in Europe
European Cell & Gene Therapy CompaniesAt NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start from, which is why we created this...
Press Release Opening NecstGen
NecstGen announces the opening of its Cell and Gene Therapy Manufacturing and Development facility. On 1 June 2022, NecstGen’s brand-new GMP manufacturing and development facility for cell and gene therapies has been opened by Henri Lenferink (Mayor of Leiden), in the...
ProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene Therapies
Leiden, Netherlands, April 26, 2022 - ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, and NecstGen, a CDMO and centre of excellence for Cell and Gene Therapy, announce a partnership for the development of...
Outsourcing Cell Therapy Manufacturing
Here are the questions you want to ask yourself when considering the outsourcing Cell Therapy Manufacturing to a CDMO. Do you have additional questions? Let us know!
NecstGen participates in € 300 million stem cell consortium
Today, the Novo Nordisk Foundation announced the € 300 million funding of an international consortium including Leiden University Medical Center, the Danstem Institute at the University of Copenhagen and the Murdoch Childrens Research Institute in Melbourne to bring...
Strategic collaboration with Cytiva
Today, NecstGen announces the strategic collaboration with Cytiva, a solutions provider in life sciences. Cytiva offers, among others, specialized expertise in industrial manufacturing of Cell and Gene Therapies. Together, NecstGen and Cytiva will share knowledge,...
NecstGen launches its first development lab
We are happy to announce the launch of NecstGen’s first development laboratory at the Leiden Bio Science Park. Here, our scientists and analytical experts have started the first process development projects, supporting our clients to bring cell- and viral vector-based...
Johan Hyllner joins strategic advisory board of NecstGen
NecstGen announces the addition of Johan Hyllner to its strategic advisory board. Johan Hyllner is leading expert in cell therapy and enabling technologies. He is professor of engineering biology at Linköping University, Sweden and head of the Cell Therapy...
